Teemu T. Junttila

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

Teemu T. Junttila, Robert W. Akita, Kathryn L. Parsons et al. · Cancer Cell · 2009 · 822 citations · Full text

Molecular Pharmacology, Signaling Pathway, Medicine +10

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab

Minna Tanner, Maija Hollmén, Teemu T. Junttila et al. · Annals of Oncology · 2005 · 656 citations

Intestinal Type, Oncology, Gastrointestinal Oncology +11

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

Teemu T. Junttila, Guangmin Li, Kathryn L. Parsons et al. · Breast Cancer Research and Treatment · 2010 · 523 citations

Breast Oncology, Oncology, Medicine +8

Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing

Ji Li, Nicola J. Stagg, Jennifer Johnston et al. · Cancer Cell · 2017 · 289 citations · Full text

Synapse Formation, Immunology, Immunoediting +16

Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies

Liping Sun, Diego Ellerman, Mary Mathieu et al. · Science Translational Medicine · 2015 · 269 citations